NHS-MMAF

• Description:

  NHS-MMAF is a modified MMAF extracted from patent WO2012143499, intermediat 219. MMAF is a potent tubulin polymerization inhibitor and is used as a antitumor agent[1]

• UNSPSC:

  12352005

• Target:

  Drug-Linker Conjugates for ADC; Microtubule/Tubulin

• Type:

  Reference compound

• Related Pathways:

  Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/nhs-mmaf.html

• Purity:

  97.20

• Solubility:

  DMSO : 112 mg/mL (ultrasonic)

• Smiles:

  OC([C@H](CC1=CC=CC=C1)NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)CCCCCC(ON3C(CCC3=O)=O)=O)=O)=O)=O)OC)=O)=O

• Molecular Formula:

  C49H78N6O12

• Molecular Weight:

  943.18

• References & Citations:

  [1]WO2012143499

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, sealed storage, away from moisture and light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1404073-19-3]